Gilead Sciences, Inc.

GILD · Nasdaq · ·

Compare

$169.73-0.7%Nov 11 close

Figures through September 30, 2026, from the 10-Q filed October 30, 2026

1W: +1.7%
1M: +14.7%

Gilead Sciences, Inc. (GILD) stock — is it a good business? — InspectStocks

Gilead Sciences, Inc.

GILD · Nasdaq · ·

Compare

$169.73-0.7%Nov 11 close

Figures through September 30, 2026, from the 10-Q filed October 30, 2026

1W: +1.7%
1M: +14.7%

Just reported

Q3 2026 results

From Gilead Sciences's results release of October 29, 2026; its quarterly report has since been filed.

Revenue
Actual
$8.3B
+6.8% y/y
+6.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1.94
-20% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
$3.46B
+4.1% y/y
Guided
—
No guide given

Company outlook

Full year 2026

EPS, GAAP$9.88+46% y/y Raised +8.8%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

How it makes money

HIV medicines73%
Liver disease medicines11%
Cancer medicines11%
Veklury1%
Royalties, contracts, and other revenue1%

Shares of revenue are estimates for six months ended June 30, 2026, not figures from a filing.

Competes with

What it sells6

Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.

Show 3 more

Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

Who buys it4

In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

What it stands on, and what could break it

What the business leans on

1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.
4Sales depend on health insurers and government payers covering medicines and on the prices and discounts they accept.

What could go wrong

1HIV medicines accounted for 72.6% of revenue (six months ended June 30, 2026, high), so changes in demand, competition, coverage, or pricing for those medicines could materially affect sales.
2Clinical trials can fail or be delayed, and regulators can limit or reject a medicine's use. In June 2026, Gilead stopped a Trodelvy study in non-small cell lung cancer and recorded a $1.75 billion impairment charge for the related research asset (three months ended June 30, 2026, high).
3Generic medicines, competing treatments, patent challenges, and required discounts or rebates can reduce sales or the amount Gilead receives for its medicines.

Full financial statements →

About Gilead Sciences, Inc.

Gilead discovers, develops, and sells prescription medicines. Its medicines prevent or treat human immunodeficiency virus (HIV), viral hepatitis, cancer, coronavirus disease 2019 (COVID-19), and other serious illnesses. It sells medicines directly through its commercial teams and through wholesalers, distributors, and business partners.

Head office: Foster City, California
Founded: 1987
Employees: Approximately 17,000 (December 31, 2025, high)
Listed on: Nasdaq
Financial year ends: December 31

Built from Gilead Sciences, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.

Just reported

Q3 2026 results

From Gilead Sciences's results release of October 29, 2026; its quarterly report has since been filed.

Revenue
Actual
$8.3B
+6.8% y/y
+6.4% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$1.94
-20% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
$3.46B
+4.1% y/y
Guided
—
No guide given

Company outlook

Full year 2026

EPS, GAAP$9.88+46% y/y Raised +8.8%

Keep exploring

The themes Gilead Sciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

How it makes money

HIV medicines73%
Liver disease medicines11%
Cancer medicines11%
Veklury1%
Royalties, contracts, and other revenue1%

Shares of revenue are estimates for six months ended June 30, 2026, not figures from a filing.

Competes with

What it sells6

Biktarvy
A daily tablet used to treat HIV infection in certain patients.
Yeztugo
A tablet and long-acting injection used before exposure to help prevent HIV infection in at-risk adults and adolescents.
Descovy
A tablet used with other medicines to treat HIV, and also used before exposure to help prevent HIV infection in certain at-risk people.

Show 3 more

Trodelvy
An intravenous medicine for certain adults with advanced breast cancer. The latest quarterly report describes its use as a first-line treatment for metastatic triple-negative breast cancer, as well as treatment for some patients with hormone-receptor-positive breast cancer.
Yescarta
A treatment made from a patient's immune cells that are changed to recognize and attack certain blood cancers.
Livdelzi
An oral medicine for primary biliary cholangitis, a chronic disease that damages small bile ducts in the liver.

Who buys it4

In the United States, large drug wholesalers buy most products for distribution to pharmacies and healthcare providers; Gilead names Cardinal Health, Cencora, and McKesson as major wholesalers.
Outside the United States, products are sold through Gilead's commercial teams, third-party distributors, and corporate partners.
Hospitals, clinics, and other healthcare providers prescribe or administer Gilead medicines to patients.
Government health programs and private insurers pay for or reimburse many prescriptions and related treatments.

What it stands on, and what could break it

What the business leans on

1Gilead relies on wholesalers to distribute most of its products in the United States and on distributors or corporate partners in some other markets.
2It relies on outside manufacturers and testing laboratories for much of the production and testing of its medicines, though it uses multiple suppliers for many products.
3Its business depends on regulatory approval and continuing compliance with rules governing drug testing, manufacture, safety, promotion, and sale.
4Sales depend on health insurers and government payers covering medicines and on the prices and discounts they accept.

What could go wrong

1HIV medicines accounted for 72.6% of revenue (six months ended June 30, 2026, high), so changes in demand, competition, coverage, or pricing for those medicines could materially affect sales.
2Clinical trials can fail or be delayed, and regulators can limit or reject a medicine's use. In June 2026, Gilead stopped a Trodelvy study in non-small cell lung cancer and recorded a $1.75 billion impairment charge for the related research asset (three months ended June 30, 2026, high).
3Generic medicines, competing treatments, patent challenges, and required discounts or rebates can reduce sales or the amount Gilead receives for its medicines.

Full financial statements →

About Gilead Sciences, Inc.

Head office: Foster City, California
Founded: 1987
Employees: Approximately 17,000 (December 31, 2025, high)
Listed on: Nasdaq
Financial year ends: December 31

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

About Gilead Sciences, Inc.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

How it makes money

Competes with

What it sells6

Who buys it4

What it stands on, and what could break it

What the business leans on

What could go wrong

About Gilead Sciences, Inc.

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Biotech

Growth & cash — 5 of 5

Business trend

Share price and grade over time